Aridis Pharmaceuticals Inc
ARDS
Get informed when a big investor buys or sells
+ FollowMarket Cap$138.18K
Close$
$-0.07
2326.7% downside
Current Fair Value
2326.7% downsideOvervalued by 2326.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $138,179.00 |
|---|---|
| Enterprise Value | $1.91 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.64 |
| Beta | -26.04 |
| Outstanding Shares | 37,428,943 |
Return
| Return on Equity | 2.69% |
|---|---|
| Return on Assets | -9.72% |
| Return on Invested Capital | 8.60% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | 0.1 |
| Enterprise Value to EBIT | -2.03 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.95 |
| Debt to Equity | -0.08 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
June 12, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 19, 2026
EPS Estimate
$-0.63
Average shareholder expectationRevenue Estimate
$450,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.01%▲ 0.01% |
|---|---|
| Total Invested | $3 |
| Investors Holding | 1▲ 1.00% |
ESG Score
No data
About Aridis Pharmaceuticals Inc
33 employeesAridis Pharmaceuticals, Inc. discovers and develops anti-infectives to be used as add-on treatments to standard-of-care antibiotics. The Company is utilizing its proprietary ?PEXTM and MabIgX® technology platforms to rapidly identify rar...